
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech Inc has demonstrated significant growth, with sales of surgical soft tissue repair products increasing by 24% year-over-year to $23.4 million, largely attributed to heightened demand for its CellerateRX Surgical Activated Collagen. Additionally, the company has seen a positive trend in its revenue for bone fusion products, which rose by 25% year-over-year to $3.1 million, indicating a robust performance across its product lines. Moreover, Sanara's strategy to expand its distribution network and penetrate additional healthcare facilities is poised to further enhance topline growth, positioning the company favorably within the medical technology sector.
Bears say
Sanara MedTech Inc reported net revenue of $26.3 million, which constitutes a year-over-year growth of 21.5%, yet this figure fell short of the projected $26.7 million. The company faces significant risks, including the potential for lower-than-expected revenue growth, challenges in customer acquisition, difficulties in launching new products and services, and the concern of dilution risk. Furthermore, a reassessment of the company's valuation led to a decrease in the EV/Revenue multiple from 4.3x to 3.0x, reflecting a negative sentiment regarding its future financial performance.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares